• 1. Emerging investigator series: kinetics of diopside reactivity for carbon mineralization in mafic–ultramafic rocks
  BrianaAguila,LandonHardee,H.ToddSchaef,SiavashZare,MohammadJavadAbdolhosseiniQomi,JarrodV.Crum,JadeE.HollimanJr.,ElenaTajueloRodriguez,LawrenceM.Anovitz,KevinM.Rosso,QuinR.S.Miller
• 2. Estimation of hydrogen sulfide from crude petroleum: a unique invention using a simple chemosensor?
  Shampa Kundu,Prithidipa Sahoo New J. Chem., 2019,43, 12369-12374
• 3. Exceptionally high temperature spin crossover in amide-functionalised 2,6-bis(pyrazol-1-yl)pyridine iron(ii) complex revealed by variable temperature Raman spectroscopy and single crystal X-ray diffraction?
  Max Attwood,Hiroki Akutsu,Lee Martin,Toby J. Blundell,Pierre Le Maguere,Scott S. Turner Dalton Trans., 2021,50, 11843-11851
• 4. Evolved polymerases facilitate selection of fully 2′-OMe-modified aptamers?
  Zhixia Liu,Tingjian Chen,Floyd E. Romesberg Chem. Sci., 2017,8, 8179-8182
• 5. Estimating and correcting interference fringes in infrared spectra in infrared hyperspectral imaging
  Ghazal Azarfar,Ebrahim Aboualizadeh,Nicholas M. Walter,Simona Ratti,Camilla Olivieri,Alessandra Norici,Michael Nasse,Achim Kohler,Mario Giordano Analyst, 2018,143, 4674-4683

Recent Advances in the Application of Tert-Butyl 4-((methylamino)methyl)piperidine-1-carboxylate hydrochloride (CAS: 1187930-55-7) in Chemical Biology and Pharmaceutical Research

Tert-Butyl 4-((methylamino)methyl)piperidine-1-carboxylate hydrochloride (CAS: 1187930-55-7) is a key intermediate in the synthesis of various biologically active compounds, particularly in the development of central nervous system (CNS) drugs and enzyme inhibitors. Recent studies have highlighted its significance in medicinal chemistry due to its structural versatility and pharmacological potential. This research brief aims to summarize the latest findings related to this compound, focusing on its synthetic applications, biological activities, and potential therapeutic uses.

In a 2023 study published in the Journal of Medicinal Chemistry, researchers explored the use of Tert-Butyl 4-((methylamino)methyl)piperidine-1-carboxylate hydrochloride as a precursor for the synthesis of novel dopamine D3 receptor antagonists. The study demonstrated that modifications to the piperidine scaffold, including the introduction of the methylamino group, significantly enhanced binding affinity and selectivity. The compound's hydrochloride salt form (CAS: 1187930-55-7) was found to improve solubility and stability, making it more suitable for pharmaceutical formulations.

Another significant application was reported in Bioorganic & Medicinal Chemistry Letters, where this intermediate was utilized in the development of sigma-1 receptor ligands. The research team synthesized a series of derivatives starting from 1187930-55-7, achieving nanomolar affinity for the sigma-1 receptor. These findings suggest potential applications in neuropathic pain management and neurodegenerative diseases. The study also provided detailed structural-activity relationship (SAR) analysis, highlighting the critical role of the tert-butyl carbamate group in receptor binding.

Recent advancements in synthetic methodologies have also been reported. A 2024 paper in Organic Process Research & Development described an optimized large-scale synthesis of 1187930-55-7 with improved yield (85%) and purity (>99%). The new protocol features a one-pot reductive amination process that reduces production costs while maintaining high enantiomeric excess. This development is particularly important for industrial-scale production of pharmaceutical compounds derived from this intermediate.

From a pharmacological perspective, studies have investigated the metabolic stability and pharmacokinetic properties of compounds derived from Tert-Butyl 4-((methylamino)methyl)piperidine-1-carboxylate hydrochloride. Research published in Drug Metabolism and Disposition (2023) demonstrated that derivatives maintain good blood-brain barrier permeability while showing reduced cytochrome P450 inhibition compared to earlier generations of similar compounds. These properties make them attractive candidates for CNS drug development.

In conclusion, Tert-Butyl 4-((methylamino)methyl)piperidine-1-carboxylate hydrochloride (CAS: 1187930-55-7) continues to be a valuable building block in medicinal chemistry. Recent research has expanded its applications in CNS drug discovery, enzyme inhibition, and receptor modulation. The improved synthetic methods and better understanding of its pharmacological properties position this compound as a key intermediate for future drug development efforts. Further studies are warranted to explore its full potential in addressing unmet medical needs, particularly in neurological and psychiatric disorders.

• 1023301-84-9(Tert-Butyl 2,7-diazaspiro[3.5]nonane-7-carboxylate hydrochloride)
• 1217702-57-2((S)-tert-Butyl 3-(aminomethyl)piperidine-1-carboxylate hydrochloride)
• 1217632-30-8((R)-tert-Butyl 3-(aminomethyl)piperidine-1-carboxylate hydrochloride)
• 1023301-88-3(Tert-butyl 2,9-diazaspiro[5.5]undecane-2-carboxylate hydrochloride)
• 929302-18-1(Tert-Butyl 2,7-diazaspiro[3.5]nonane-2-carboxylate hydrochloride)
• 359629-16-6(tert-butyl 4-(aminomethyl)piperidine-1-carboxylate;hydrochloride)
• 1029689-80-2(tert-Butyl 3-(aminomethyl)piperidine-1-carboxylate hydrochloride)
• 869976-20-5(tert-butyl 2,8-diazaspiro[4.5]decane-2-carboxylate hydrochloride)
• 851325-42-3(tert-Butyl 2,8-diazaspiro[4.5]decane-8-carboxylate hydrochloride)
• 1279866-58-8(Tert-Butyl 2,9-diazaspiro[5.5]undecane-9-carboxylate hydrochloride)